Do you want to read an article? Please log in or register.
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial - Cardiovascular Safety of Linagliptin vs. Glimepiride
Type 2 Diabetes
COMMENTED
Related content
Type 2 Diabetes
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
JAMA.
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N, CAROLINA Investigators.
doi: 10.1001/jama.2019.13772.
Type 2 DiabetesGlycemic Control
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial
Diabetes Obes Metab
Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE
doi: 10.1111/dom.14254
COMMENTED
Type 2 Diabetes
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M
doi: 10.1016/S2213-8587(19)30384-5.
COMMENTED
Lipids
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S
doi: 10.1016/S0140-
Diabetes - GeneralGlycemic Control
Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis
Diabetes Care.
Mannucci E, Mosenzon O, Avogaro A
doi: 10.2337/dcS15-3024.
Type 2 Diabetes
Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK
Diabetes Obes Metab
Webb J, Mount J, von Arx LB, Rachman J, Spanopoulos D, Wood R, Tritton T, Massey O, Idris I
doi: 10.1111/dom.14580
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
COMMENTED
Diabetes - GeneralType 2 Diabetes
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
Diabetes Care.
Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH
doi: 10.2337/dc16-2725.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).
Diabetes Care.
Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group
doi: 10.2337/dc16-1135.